Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD
Who is this study for? Patients with attention-deficit/hyperactivity disorder
What treatments are being studied? Methylphenidate
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The investigators' goal is to develop neuroimaging biomarkers to predict response to treatment with methylphenidate, which then can be used in the development of novel pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD). The overall objective of this study is to measure the changes in task-related neural activity related to symptoms of ADHD (measured by functional MRI) and brain glutamate levels (measured by magnetic resonance spectroscopy, MRS) after treatment with methylphenidate (MPH). This will be a double-blind crossover of methylphenidate and placebo in adults with ADHD. Participants will complete neuropsychological testing along with fMRI and MRS scans after a single dose of each treatment.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Maximum Age: 40
Healthy Volunteers: f
View:
• right handed
Locations
United States
Maryland
Johns Hopkins School of Medicine
RECRUITING
Baltimore
Contact Information
Primary
Kristin L Bigos, PhD
kbigos1@jhu.edu
410-614-0453
Backup
Robyn Wiseman, BS
rwisema5@jhmi.edu
304-551-3309
Time Frame
Start Date: 2021-07-27
Estimated Completion Date: 2026-05-01
Participants
Target number of participants: 30
Treatments
Experimental: Methylphenidate first
Single oral dose of methylphenidate (10mg or 15 mg) and then matching placebo after washout period of one week.
Placebo_comparator: Placebo first
Matching placebo and then single oral dose of methylphenidate (10mg or 15 mg) after washout period of one week.
Related Therapeutic Areas
Sponsors
Collaborators: National Institutes of Health (NIH)
Leads: Johns Hopkins University